Comments
Loading...
Stime degli utili, EPS e fatturato
Rigel Pharmaceuticals segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
nov 6
Stima EPS
$0.770
Stima dei ricavi trimestrali
$60.36M
Ricavi annuali
(a partire da giu 30)
(a partire da giu 30)
$267.92M
Analizza lo storico degli utili di Rigel Pharmaceuticals utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
RIGL | Rigel Pharmaceuticals | $0.70 | $0.77 | — | — | $55.31M | $60.36M | — | — | 11/06/2025 | |
RIGL | Rigel Pharmaceuticals | -$0.06 | $1.63 | $3.28 | 101.23% | $36.84M | $75.08M | $101.69M | 35.43% | 08/05/2025 | |
RIGL | Rigel Pharmaceuticals | -$0.50 | $0.09 | $0.63 | 600.00% | $29.53M | $43.87M | $53.30M | 21.50% | 05/06/2025 | |
RIGL | Rigel Pharmaceuticals | $0.04 | $0.55 | $0.80 | 45.45% | $35.79M | $57.59M | $57.60M | 0.01% | 03/04/2025 | |
RIGL | Rigel Pharmaceuticals | -$0.30 | $0.06 | $0.70 | 1066.67% | $28.13M | $41.93M | $55.31M | 31.90% | 11/07/2024 | |
RIGL | Rigel Pharmaceuticals | -$0.38 | -$0.29 | -$0.06 | 79.31% | $26.89M | $33.42M | $36.84M | 10.24% | 08/06/2024 | |
RIGL | Rigel Pharmaceuticals | -$0.80 | -$0.30 | -$0.50 | -66.67% | $26.07M | $31.28M | $29.53M | -5.58% | 05/07/2024 | |
RIGL | Rigel Pharmaceuticals | $0.10 | -$0.30 | $0.00 | 100.00% | $51.28M | $34.10M | $35.79M | 4.96% | 03/05/2024 | |
RIGL | Rigel Pharmaceuticals | -$1.10 | -$0.70 | -$0.30 | 57.14% | $22.41M | $27.20M | $28.13M | 3.43% | 11/07/2023 | |
RIGL | Rigel Pharmaceuticals | -$0.80 | -$0.80 | -$0.40 | 50.00% | $29.82M | $26.02M | $26.89M | 3.33% | 08/01/2023 | |
RIGL | Rigel Pharmaceuticals | -$1.60 | -$1.00 | -$0.80 | 20.00% | $16.73M | $24.07M | $26.07M | 8.31% | 05/02/2023 | |
RIGL | Rigel Pharmaceuticals | -$1.10 | -$1.10 | $0.10 | 109.09% | $20.41M | $27.97M | $51.28M | 83.33% | 03/07/2023 | |
RIGL | Rigel Pharmaceuticals | -$1.20 | -$1.30 | -$1.10 | 15.38% | $21.54M | $22.61M | $22.41M | -0.88% | 11/03/2022 | |
RIGL | Rigel Pharmaceuticals | -$0.80 | -$1.20 | -$0.80 | 33.33% | $26.27M | $23.65M | $29.82M | 26.08% | 08/02/2022 | |
RIGL | Rigel Pharmaceuticals | $2.20 | -$1.40 | -$1.60 | -14.29% | $81.02M | $17.54M | $16.73M | -4.59% | 05/03/2022 | |
RIGL | Rigel Pharmaceuticals | -$1.10 | -$1.30 | -$1.10 | 15.38% | $18.45M | $21.90M | $20.41M | -6.81% | 03/01/2022 | |
RIGL | Rigel Pharmaceuticals | -$0.80 | -$1.00 | -$1.20 | -20.00% | $18.39M | $23.56M | $21.54M | -8.56% | 11/02/2021 | |
RIGL | Rigel Pharmaceuticals | -$1.00 | -$1.10 | -$0.80 | 27.27% | $16.02M | $20.37M | $26.27M | 28.94% | 08/03/2021 | |
RIGL | Rigel Pharmaceuticals | $1.30 | — | $2.20 | — | $55.76M | $31.05M | $81.02M | 160.93% | 05/05/2021 | |
RIGL | Rigel Pharmaceuticals | -$1.00 | -$1.10 | -$1.10 | 0.00% | $15.40M | $18.10M | $18.45M | 1.93% | 03/02/2021 | |
RIGL | Rigel Pharmaceuticals | -$0.70 | — | -$0.80 | — | $9.14M | — | $18.39M | — | 11/05/2020 |
Rigel Pharmaceuticals (RIGL) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-05 | $3.28 | $1.63 | 101.2 % |
| Q1 | 2025-05-06 | $0.63 | $0.09 | 600.0 % |
| Q4 | 2025-03-04 | $0.80 | $0.55 | 45.5 % |
| Q3 | 2024-11-07 | $0.70 | $0.06 | 1066.7 % |
Rigel Pharmaceuticals (RIGL) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-05 | $101.69M | $75.08M | 35.4 % |
| Q1 | 2025-05-06 | $53.30M | $43.87M | 21.5 % |
| Q4 | 2025-03-04 | $57.60M | $57.59M | 0.01 % |
| Q3 | 2024-11-07 | $55.31M | $41.93M | 31.9 % |
FAQ
Quando Rigel Pharmaceuticals (NASDAQ:RIGL) riporterà gli utili?
Si prevede che Rigel Pharmaceuticals (RIGL) fornisca risultati il novembre 6, 2025. Gli ultimi risultati sono stati pubblicati il agosto 5, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Rigel Pharmaceuticals (NASDAQ:RIGL)?
L'EPS effettivo era $3.28, che superato la stima di $1.63.
Quali sono state le entrate di Rigel Pharmaceuticals (NASDAQ:RIGL)?
Le entrate effettive sono state $101.7M, che superato la stima di $75.1M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.